UNC Institute for Global Health & Infectious Diseases | Strategic Alliance Partners

This podcast series details the ins and outs of managing, preventing, and treating HIV, from the perspective of the faculty and patients of the UNC Institute for Global Health & Infectious Diseases.

Misinformation about clinical research, mistrust between scientists and the community, and HIV-related stigma often impede efforts to find an HIV cure.

The fight against the acquired immunodeficiency syndrome (AIDS) epidemic has made huge strides in recent years, but there is still much more work to be done. What role technology will play in that effort has yet to be determined.

There are several areas of the country where the acquired immunodeficiency syndrome (AIDS) epidemic remains to be a problem. Both minorities and those in the southern states are seeing a continued problem with the disease, while the northern states are seeing improvements in numbers.

As the battle against the acquired immunodeficiency syndrome (AIDS_ epidemic continues, a project funded by the National Institutes of Health (NIH) is looking at different ways to use technology to help in the prevention and care of the human immunodeficiency virus (HIV) and AIDS.

Although prenatal human immunodeficiency virus (HIV) transmission has declined by 90% since the early 1990s, the need for studies focusing are pregnant women with HIV are very much needed.

Untreated pregnant women with the human immunodeficiency virus (HIV) will transmit the infection to their child up to 45% of the time. But a new anti-HIV medication could lower that percentage.

Researchers from the University of North Carolina (UNC) analyzed how the human immunodeficiency virus (HIV) attacks macrophages – a target that, up until now, was believed to have little to do with infection.

Pre-clinical study results appear to demonstrate the efficacy of a new long-acting formulation of the HIV medication raltegravir in preventing vaginal transmission of HIV in animal models.

If research continues focusing on macrophages and their role in the human immunodeficiency virus (HIV), it could mean new opportunities to treat patients and eventually help find a cure.

In previous studies it had been shown that macrophages were not targeted by HIV when looking at how the virus develops. New research of mouse models has shown evidence that that may not be the case.

The human immunodeficiency virus (HIV) is no longer the death sentence it was when the virus was first discovered in 1983. Although patients are living better, longer lives, finding a cure to the disease remains a top priority.

Through 30 years of research HIV has gone from being a death sentence for patients to something that can be more of a chronic condition. Antiretroviral therapy has been a key part of that fight and now there is more good news about this treatment option.